

Hyeon Jeong Suh

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1095955/hyeon-jeong-suh-publications-by-citations.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

11

papers

239

citations

7

h-index

12

g-index

12

ext. papers

320

ext. citations

5.6

avg, IF

3.84

L-index

#	Paper	IF	Citations
11	Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2021, 27,	10.2	67
10	Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2021, 27, 928-931	10.2	66
9	Antibody Responses to SARS-CoV-2 at 8 Weeks Postinfection in Asymptomatic Patients. <i>Emerging Infectious Diseases</i> , 2020, 26, 2484-2487	10.2	50
8	The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62,	5.9	15
7	Clinical Characteristics of COVID-19: Clinical Dynamics of Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection Detected by Early Active Surveillance. <i>Journal of Korean Medical Science</i> , 2020, 35, e297	4.7	13
6	Antibody Responses One Year after Mild SARS-CoV-2 Infection. <i>Journal of Korean Medical Science</i> , 2021, 36, e157	4.7	9
5	Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies. <i>Infection and Chemotherapy</i> , 2017, 49, 135-139	3.9	7
4	Clinical Characteristics of COVID-19: Risk Factors for Early Oxygen Requirement after Hospitalization. <i>Journal of Korean Medical Science</i> , 2021, 36, e139	4.7	4
3	Prevalence of cryptococcal antigenemia in hospitalized patients with liver cirrhosis. <i>Medical Mycology</i> , 2020, 58, 207-210	3.9	3
2	Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 115-119	3.2	3
1	A Risk-Scoring System for Predicting Methicillin Resistance in Community-Onset <i>Staphylococcus aureus</i> Bacteremia in Korea. <i>Microbial Drug Resistance</i> , 2018, 24, 556-562	2.9	1